

# India

| High TB burden | High HIV burden | High MDR-TB burden |

## Tuberculosis profile

Population 2013

1 252 million

Estimates of TB burden * 2013	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	240 (150–350)	19 (12–28)
Mortality (HIV+TB only)	38 (31–44)	3 (2.5–3.5)
Prevalence (includes HIV+TB)	2 600 (1 800–3 700)	211 (143–294)
Incidence (includes HIV+TB)	2 100 (2 000–2 300)	171 (162–184)
Incidence (HIV+TB only)	120 (100–140)	9.7 (8.3–11)
Case detection, all forms (%)	58 (54–61)	

Estimates of MDR-TB burden * 2013	New	Retreatment
% of TB cases with MDR-TB	2.2 (1.9–2.6)	15 (11–19)
MDR-TB cases among notified pulmonary TB cases	20 000 (17 000–24 000)	41 000 (30 000–52 000)

TB case notifications 2013	New **	Relapse
Pulmonary, bacteriologically confirmed	621 762	102 660
Pulmonary, clinically diagnosed	292 926	
Extrapulmonary	226 557	

<b>Total new and relapse</b>	<b>1 243 905</b>
Previously treated, excluding relapses	171 712
<b>Total cases notified</b>	<b>1 415 617</b>

Among 1 243 905 new and relapse cases:  
64 726 (5%) cases aged under 15 years;

Reported cases of RR-/MDR-TB 2013	New	Retreatment	Total **
Cases tested for RR-/MDR-TB			248 341
Laboratory-confirmed RR-/MDR-TB cases			35 385
Patients started on MDR-TB treatment			20 763

TB/HIV 2013	Number	(%)
TB patients with known HIV status	887 903	(63)
HIV-positive TB patients	44 027	(5)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	41 827	(95)
HIV-positive TB patients on antiretroviral therapy (ART)	38 754	(88)
HIV-positive people screened for TB	1 063 644	
HIV-positive people provided with IPT		

Treatment success rate (%)	(%)
New and relapse cases registered in 2012	88
Previously treated cases, excluding relapse, registered in 2012	74
HIV-positive TB cases, all types, registered in 2012	77
RR-/MDR-TB cases started on second-line treatment in 2011	50
XDR-TB cases started on second-line treatment in 2011	


Laboratories 2013	
Smear (per 100 000 population)	1.0
Culture (per 5 million population)	0.2
Drug susceptibility testing (per 5 million population)	0.2
Sites performing Xpert MTB/RIF	54
Is second-line drug susceptibility testing available?	Yes, in country

Financing TB control 2014	
National TB programme budget (US\$ millions)	252
% Funded domestically	66%
% Funded internationally	34%
% Unfunded	0%

\* Ranges represent uncertainty intervals


\*\* Includes cases with unknown previous TB treatment history

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population)




Prevalence

(Rate per 100 000 population per year)




Notified (new and relapse) Incidence  
Incidence (HIV+TB only)

(Number of patients)




HIV-positive TB patients  
on CPT on ART

Treatment success rate (%)



New Retreatment  
New and relapse Retreatment, excluding relapse  
HIV-positive RR-/MDR-TB XDR-TB

Total budget (US\$ millions)



Funded domestically Funded internationally  
Unfunded